Atea Pharmaceuticals, Inc. (AVIR)

Over the past six months, Atea Pharmaceuticals' stock has experienced several impacts. On August 7, 2025, the stock declined by 2.31% after Q2 2025 financial results were reported, including a net loss of $37.2 million. On November 12, 2025, the stock saw a 3.25% rise in aftermarket trading despite missing EPS forecasts, as the company completed a share repurchase program and projected a financial runway through 2027. On December 22, 2025, patient enrollment was completed in its North American Phase 3 trial for the bemnifosbuvir and ruzasvir regimen for HCV. On January 6 and 8, 2026, Atea announced its participation at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its 2026 strategic priorities, including anticipated topline results from its HCV Phase 3 trials in mid-2026 and year-end 2026, and the planned initiation of a Phase 1 clinical program for AT-587 for HEV in mid-2026. Overall, the stock has decreased by 3.00% over the last six months.

Reliable seasonal analysis for Atea Pharmaceuticals is challenging due to only four years of available data. The Healthcare sector, in which Atea operates, generally experiences seasonal strength from April 25 to December 4. A historical seasonal timeframe of May 3 to July 23 has shown positive results for AVIR compared to the S&P 500 Total Return Index over the past four years.

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics. Their lead product candidates include bemnifosbuvir for COVID-19 and a combination of bemnifosbuvir and ruzasvir for Hepatitis C virus (HCV), which is in Phase 3 clinical trials. They also have a license agreement with MSD International GmbH for ruzasvir and are advancing AT-587 for Hepatitis E virus (HEV) into Phase 1 trials.

Atea Pharmaceuticals is headquartered in Boston, Massachusetts, United States. Its HCV Phase 3 trials are global, but specific details about its broader operational or commercial geographic footprint beyond its US headquarters are not extensively disclosed.

Information specifically detailing Atea Pharmaceuticals' brand reputation or events that have directly impacted it in the past year is not readily available. The available data primarily focuses on financial performance, clinical trial progress, and corporate announcements.

Atea Pharmaceuticals has a mixed ownership structure, with institutional shareholders holding the majority. Major institutional owners include BlackRock, Inc., BML Capital Management, LLC, Fmr Llc, Tang Capital Management Llc, Vanguard Group Inc, Bain Capital Life Sciences Investors, LLC, Geode Capital Management, Llc, iShares Russell 2000 ETF, and State Street Corp. Insiders hold approximately 10.42% of the company's stock, with Jean-Pierre Sommadossi, the CEO and Founder, being a significant individual shareholder. Retail investors hold about 4.22% of the company.